Within the community of microorganisms inhabiting the human body, the fungus Candida normally harbors different sites, such as the skin, mouth, gut, and vaginal mucosa, without causing any harm. However, if the immune defense is weakened, such as during antibiotic treatments, diabetes, or immunosuppressive therapy, Candida can become invasive and cause infection. Moreover, around 75% of women worldwide of childbearing age suffer of vaginal infections at least once during their life. This condition results in diminished quality of life as well as increased associated healthcare costs.
Specific Candida strains have been suggested to play a role in vaginal candidiasis. Within the European Horizon 2020 project FunHoMic, the authors performed a research project to identify the immune response profile to Candida africana, a Candida species that has been suggested to specifically cause vaginal infections. The results of this study by Diletta Rosati and her colleagues from the teams of Prof. Mihai Netea from the Internal Medicine Department and Prof. Jacques Meis from CWZ, were published in Medical Mycology on October 12th.
Using purified human immune cells isolated from healthy volunteers, they studied the capacity of various clinical strains of Candida africana from different geographical locations to stimulate host defense mechanisms. They assessed both differences between Candida africana isolates (intra-species) and among different Candida species (inter-species) that are commonly found in the clinic. It was found that C. Africana induces broadly a similar cytokine response in comparison to the other Candida species and we concluded that the type of strain is most likely not the main factor causing vulvovaginal candidiasis. The most likely cause of the disease is therefore the host interindividual differences. Their results expand the knowledge and contribute to understand the pathogenesis of candida vaginitis.
Publication
Rosati D., Bruno M., Van de Veerdonk F., Ten Oever J., Meis JF, Netea MG. Activation of cytokine responses by Candida africana. Medical Mycolog. 2022 Oct 12;60(10):myac080. doi: 10.1093/mmy/myac080. PMID: 3619532
Related news items

Joint research in regional hospitals New research projects from promotion fund
22 November 2022Four research projects have been honored in the promotion fund of the Radboudumc and four regional hospitals. The research projects, which are a collaboration between CWZ, Jeroen Bosch Hospital, Rijnstate, Sint Maartenskliniek and the Radboudumc will receive a contribution of 240,000 euros.
read more
Trained immunity’s role in kidney disease
17 November 2022Researcher(s) Jordi Ochando of the Icahn School of Medicine at Mount Sinai in New York and Raphaël Duivenvoorden of the Department of Nephrology at Radboudumc explain how trained immunity can have detrimental effects in kidney disease and transplantation.
read more